| Identification | Back Directory | [Name]
4-(2-Chlorophenoxy)-N-[3-[(methylamino)carbonyl]phenyl]-1-Piperidinecarboxamide | [CAS]
1032229-33-6 | [Synonyms]
A939572
1032229-33-6
SCD inhibitor
A939572;A-939572;A 939572
stearoyl-CoA desaturase (SCD) inhibitor
4-(2-Chlorophenoxy)-N-[3-[(methylamino)carbonyl]phenyl]-1-Piperidinecarboxamide
4-(2-Chlorophenoxy)-N-(3-(methylcarbamoyl)-phenyl)piperidine-1-carboxamide (A939572) | [Molecular Formula]
C20H22ClN3O3 | [MOL File]
1032229-33-6.mol | [Molecular Weight]
387.86 |
| Chemical Properties | Back Directory | [Boiling point ]
633.5±55.0 °C(Predicted) | [density ]
1.302±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
insoluble in H2O; ≥17.15 mg/mL in DMSO; ≥2.5 mg/mL in EtOH with ultrasonic | [form ]
solid | [pka]
13.65±0.70(Predicted) | [color ]
White to off-white | [InChI]
InChI=1S/C20H22ClN3O3/c1-22-19(25)14-5-4-6-15(13-14)23-20(26)24-11-9-16(10-12-24)27-18-8-3-2-7-17(18)21/h2-8,13,16H,9-12H2,1H3,(H,22,25)(H,23,26) | [InChIKey]
DPYTYQFYDLYWHZ-UHFFFAOYSA-N | [SMILES]
N1(C(NC2=CC=CC(C(NC)=O)=C2)=O)CCC(OC2=CC=CC=C2Cl)CC1 |
| Hazard Information | Back Directory | [Uses]
4-(2-Chlorophenoxy)-N-[3-[(methylamino)carbonyl]phenyl]-1-piperidinecarboxamide is a stearoyl-CoA desaturase 1 (SCD1) inhibitor. | [Biological Activity]
a939572 is a potent and orally bioavailable inhibitor of stearoyl-coa desaturase1 (scd1) with ic50 value of 37nm [1].scd is a microsomal enzyme that catalyzes the biosynthesis of monounsaturated fatty acids. one member of scd family, scd1, is regulated by dietary and hormonal factors and is proved to play an important role in lipid metabolism and body weight control. thus, scd1 is a target for the treatment of obesity and diabetes. a939572 is a synthetic inhibitor of scd1 with improved inhibitory activity and lipophilicity than its parent compound. it shows inhibition of mouse scd1 and human scd1 with ic50 values of | [in vivo]
Athymic nude (nu/nu) mice bearing A498 ccRCC xenografts are treated with A939572 (30mg/kg, p.o.) and Tem individually or in combination over the course of four weeks, and tumor volume (mm3) is recorded. A939572 and Tem monotherapy generate similar growth responses with approximately 20-30% reductions in tumor volume (vs. placebo control) being observed upon study completion, with values reaching statistical significance only within the last week of treatment. The combination group yields over a 60% decrease in tumor volume (vs. placebo control) by study completion with significant reductions recorded after approximately 1 week of treatment[2]. | [storage]
Store at -20°C | [References]
[1] xin z, zhao h, serby m d, et al. discovery of piperidine-aryl urea-based stearoyl-coa desaturase 1 inhibitors. bioorganic & medicinal chemistry letters, 2008, 18(15): 4298-4302. |
|
| Company Name: |
SynAsst Chemical.
|
| Telephone: |
021-60343070 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList15848/0_EN.htm |
| Company Name: |
LETOPHARM LIMITED
|
| Telephone: |
+86-21-5821 5861 |
| Website: |
www.letopharm.com |
| Company Name: |
SPIRO PHARMA
|
| Telephone: |
|
| Website: |
www.spiropharma.com.cn |
|